Clinical Trial

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2025 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-11-22; most recent amendment 2025-04-07.
Status change: Not Yet Recruiting → Recruiting 2023-03-21
Trial Details
NCT Number NCT05626530
Lead Sponsor Tufts Medical Center
Conditions Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
Enrollment 25 participants
Start Date 2023-02-02
Primary Completion 2025-12-15 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-04-10